Target organ toxicities in studies conducted to support first time in man dosing: An analysis across species and therapy areas

Regulatory Toxicology and Pharmacology

Volumn 65, Issue 3, 2013, Pages 334-343

  Horner, Steve ^a   Ryan, David ^a   Robinson, Sally ^a   Callander, Richard ^a   Stamp, Katie ^a   Roberts, Ruth A ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

Candidate drugs; First time in man; Pre clinical studies; Target organ toxicities; Toxicity profile

Indexed keywords

NEW DRUG;

ADRENAL GLAND; ARTICLE; BONE MARROW TOXICITY; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; DRUG SAFETY; DRUG TOLERABILITY; GASTROINTESTINAL DISEASE; GASTROINTESTINAL TOXICITY; HISTOPATHOLOGY; INFECTION; INFLAMMATION; LIVER TOXICITY; NEOPLASM; NEPHROTOXICITY; NONHUMAN; PAIN; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; SPECIES DIFFERENCE; SPLEEN; TARGET ORGAN; TESTIS; THYMUS; TOXICITY TESTING;

ANIMALS; ANIMALS, LABORATORY; CENTRAL NERVOUS SYSTEM; DRUG EVALUATION, PRECLINICAL; DRUG-INDUCED LIVER INJURY; DRUGS, INVESTIGATIONAL; FEMALE; GENITALIA, MALE; HUMANS; LIVER; MALE; RISK ASSESSMENT; SPECIES SPECIFICITY; TOXICITY TESTS;

EID: 84875256110     PISSN: 02732300     EISSN: 10960295     Source Type: Journal    
DOI: 10.1016/j.yrtph.2013.02.002     Document Type: Article

References (19)

1. Baldrick P. Safety evaluation to support first-in-man investigations II: toxicology studies. Regul. Toxicol. Pharmacol. 2008, 51:237-243.
2. Ballet F. Hepatotoxicity in drug development: detection, significance and solutions. J. Hepatol. 1997, 26(Suppl. 2):26-36.
3. Broadhead C.L., Betton G., Combes R., Damment S., Everett D., Garner C., Godsafe Z., Healing G., Heywood R., Jennings M., Lumley C., Oliver G., Smith D., Strauhgan D., Topham J., Wallis R., Wilson S., Buckley P. Prospects for reducing and refining the use of dogs in the regulatory toxicity testing of pharmaceuticals. Hum. Exp. Toxicol. 2000, 19:440-447.
4. FDA Guidance for Industry, 2005. Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers. (last accessed 09 November 2012). http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM078932.pdf.
5. Greaves P., Williams A., Eve M. First dose of potential new medicines to humans: how animals help. Nat. Rev. Drug Discovery 2004, 3:226-236.
6. Greaves P. Histopathology of Preclinical Toxicity Studies 2007, Academic Press, Elsevier, New York. third ed.
7. Hall A., Westwood F., Wadsworth P. Review of the effects of anti-angiogenic compounds on the epiphyseal growth plate. Toxicol. Pathol. 2006, 34:131-147.
8. Haruyama E., Suda M., Ayukawa Y., Kamura K., Mizutamari M., Ooshima Y., Tanimoto A. Testicular development in cynomolgus monkeys. Toxicol. Pathol. 2012, 40:935-942.
9. Heywood R. Target organ toxicity. Toxicol. Lett. 1981, 8:349-358.
10. ICH Guideline M3(R2), 2009. Guidance on Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals. (last accessed 09 November 2012). http://www.ich.org/products/guidelines/multidisciplinary/article/multidisciplinary-guidelines.html.
11. ICH Guideline S9, 2009. Nonclinical Evaluation for Anticancer Pharmaceuticals. (last accessed 09 November 2012). http://www.ich.org/products/guidelines/safety/article/safety-guidelines.html.
12. Kramer J., Sagartz J., Morris D. The application of discovery toxicology and pathology towards the design of safer pharmaceutical lead candidates. Nat. Rev. Drug Discovery 2007, 6:636-649.
13. Lanning L., Creasy D., Chapin R., Mann P., Barlow N., Regan K., Goodman D. Recommended approaches for the evaluation of testicular and epididymal toxicity. Toxicol. Pathol. 2002, 30:507-520.
14. Olson H., Betton G., Robinson D., Thomas K., Monro A., Kolaja G., Lilly P., Sanders J., Sipes G., Bracken W., Dorato M., Van Deun K., Smith P., Berger B., Heller A. Concordance of the toxicity of pharmaceuticals in humans and in animals. Regul. Toxicol. Pharmacol. 2000, 32:56-67.
15. Robinson, S., Chapman, K., Hudson, S., Sparrow, S., Spencer-Briggs, D., Danks, A., Hill, R., Everett, D., Mulier, B., Old, S., Bruce, C., 2009. Guidance on dose level selection for regulatory general toxicology studies for pharmaceuticals. (last accessed 09 November 2012). http://www.nc3rs.org.uk/downloaddoc.asp?id=1108&page=1428&skin=0.
16. Rosenfeldt H., Kropp T., Benson K., Ricci S., McGuinn D., Verbois L. Regulatory aspects of oncology drug safety evaluation: past practice, current issues, and the challenge of new drugs. Toxicol. Appl. Pharmacol. 2010, 243:125-133.
17. Sasaki J., Chapin R., Hall D., Breslin W., Moffit J., Saldutti L., Enright B., Seger M., Jarvi K., Hixon M., Mitchard T., Kim J. Incidence and nature of testicular toxicity findings in pharmaceutical development. Birth Defects Res. B 2011, 92:511-525.
18. Senderowicz A.M. Information needed to conduct first-in-human oncology trials in the United States: a view from a former FDA medical reviewer. Clin. Cancer Res. 2010, 16:1719-1725.
19. Zühlke U., Weinbauer G. The common marmoset (Callithrix jacchus) as a model in toxicology. Toxicol. Pathol. 2003, 31:123-127.